Article
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.
Blood - 25 Aug 2011
van Vlijmen Elizabeth F W, Veeger Nic J G M, Middeldorp Saskia, Hamulyák Karly, Prins Martin H, Büller Harry R, Meijer Karina
Abstract excerpt
Current guidelines discourage combined oral contraceptive (COC) use in women with hereditary thrombophilic defects. However, qualifying all hereditary thrombophilic defects as similarly strong risk factors might be questioned. Recent studies indicate the risk of venous thromboembolism (VTE) of a factor V Leiden mutation as considerably lower than a deficiency of protein C, protein S, or antithrombin. In a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.